Immune Checkpoints Mediate Tumor Immune Regulation
through Metabolic Pathways.
10.3779/j.issn.1009-3419.2025.106.08
- Author:
Weiguang DU
1
;
Xiyang TANG
2
;
Yulong ZHOU
2
;
Mengchao LI
2
;
Ze JIN
3
;
Jiaqi DOU
3
;
Jinbo ZHAO
2
Author Information
1. Graduate School of Xi'an Medical University, Xi'an 710021, China.
2. Department of Thoracic Surgery, Tangdu Hospital, Air
Force Medical University, Xi'an 710038, China.
3. College of Basic Medicine, Air Force Medical University, Xi'an 710032, China.
- Publication Type:English Abstract
- Keywords:
Immune checkpoints;
Immune metabolism;
Tumor immune;
Tumor microenvironment
- MeSH:
Humans;
Neoplasms/genetics*;
Metabolic Networks and Pathways/immunology*;
Animals;
Immune Checkpoint Inhibitors/pharmacology*
- From:
Chinese Journal of Lung Cancer
2025;28(3):213-220
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoints include a series of receptor-ligand pairs that play a key role in the proliferation, activation, and immune regulatory responses of immune cells. Although immune checkpoint inhibitors (ICIs), such as programmed death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have achieved good therapeutic effects in clinical practice, some patients still experience ineffective treatment and immune resistance. A large amount of evidence has shown that immune checkpoint proteins are related to cell metabolism during immune regulation. On the one hand, immune checkpoints connect to alter the metabolic reprogramming of tumor cells to compete for nutrients required by immune cells. On the other hand, immune checkpoints regulate the metabolic pathways of immune cells, such as phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) to affect the activation of immune cells. Based on a review of the literature, this article reviews the mechanisms by which PD-1, CTLA-4, T cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), cluster of differentiation 47 (CD47), and indoleamine 2,3-dioxygenase 1 (IDO1) regulate cell metabolic reprogramming, and looks forward to whether targeting the ligand-receptor pairs of immune checkpoints in a "dual regulation" manner and inhibiting metabolic pathways can effectively solve the problem of tumor immune resistance.
.
